Investing.com - 伯恩斯坦法兴集团周四将安进 (NASDAQ:AMGN)的目标价从350.00美元下调至335.00美元，同时维持对该股票的"优于大市"评级。根据 InvestingPro 数据，该股票目前的市盈率为23.5倍，分析师目标价范围从185美元到405美元不等。

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

该研究公司强调了安进的强劲销售表现，特别是其Evenity和Imdelltra产品，这些表现使Cantor Fitzgerald模型中的更高估计得到了证实。这一表现促成了安进稳健的股息状况，该公司已连续15年保持股息支付，目前收益率为3.3%。

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $328.83, a 15.51% upside from current levels. In a report released yesterday, Citi also maintained a Hold ...